In contrary to the downregulation of IDO, a recent phase I clinical trial evaluating epidermal growth factor receptor variant III (EGFRvIII)-targeted chimeric antigen receptor (CAR) T cell therapy in GBM patients demonstrated a dramatic induction of intratumoral IDO expression after the adoptive transfer of CAR T cells (116). Here, IDO1 is linked to glioblastoma.